Joelle Kefer - Future in nephrology: LAAO for end stage renal failure
About this lecture
Patients suffering from AF and end stage renal failure. Are these patients forgotten as an important target group for left atrial appendage occlusion therapy? Do we need to do more to involve nephrologists?
David Hildick Smith - What’s new: clinical data published and presented since last year
New clinical data for left atrial appendage occlusion therapy, presented & published in 2016. Includes a critical review of the Stroke Prevention section in the 2016 ESC Atrial Fibrillation guidelines.
Matthew Price - What’s new: cost effectiveness and health economics
Why might LAA occlusion therapy be cost effective, despite a high procedural cost? This presentation is an overview of the health economics data available for left atrial appendage closure therapy.
John Camm, Hans Christop Diener - Debate: Are the new ESC guidelines too strict for LAA Occlusion?
John Camm, UK vs Hans Christoph Diener, DEU Debate: Are the new ESC guidelines are too strict for Left Atrial Appendage Occlusion? John Camm - Yes, they are too strict. There is a larger group that should benefit from LAA occlusion and it should be stronger recommended too!Hans Christoph Diener - No, the ESC guidelines are right; LAA occlusion Should be limited to OAC contraindicated patients!